The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Venetoclax-based regimens showed a trend toward improved survival compared to BTK inhibitors, although subgroup sizes were small.